ArticleJournal of the American Society of Nephrology : JASN2026
Platelet Cyclophilin D Drives Cholesterol Crystal Embolism-Related Acute Kidney Injury and Kidney Infarction.
Article in Journal of the American Society of Nephrology : JASN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
key pointsCholesterol crystal embolism causes arterial thrombosis, ischemic necrosis, and organ dysfunction. Genetic depletion of cyclophilin D reduced cholesterol crystal embolism-induced thromboinflammation and protected organ function. Pharmacological inhibition of cyclophilin D and transmembrane protein 16F limited cholesterol crystal embolism-induced thrombosis and improved kidney function.
backgroundCholesterol crystal embolism is a severe consequence of advanced atherosclerosis, where intra-arterial cholesterol crystal can trigger organ injury and failure. Cyclophilin D (CypD), a key regulator of the mitochondrial permeability transition pore, promotes procoagulant platelet formation and necrosis. We hypothesized that CypD-dependent procoagulant platelet formation enhances cholesterol crystal embolism-induced thromboinflammatory responses and kidney injury.
methodsWe used CypD-deficient mice and pharmacologic inhibitors (cyclosporine A to block CypD and niflumic acid to inhibit transmembrane protein 16F as a downstream effector of CypD) to determine the role of CypD during cholesterol crystal-induced kidney thromboinflammation and injury.
resultsCholesterol crystal injection into the renal artery caused infarction, thromboinflammation, and AKI in wild-type mice, whereas CypD-deficient mice were protected. Global or platelet-specific CypD deletion preserved GFR, reduced infarct size, and attenuated tubular damage. Pharmacological inhibition of CypD with cyclosporin A conferred similar protection. Inhibition of transmembrane protein 16F-dependent phosphatidylserine exposure with niflumic acid also reduced CypD-mediated procoagulant activity and limited kidney injury.
conclusionsOur findings identified platelet CypD and downstream phosphatidylserine exposure as key mediators of cholesterol crystal-induced thromboinflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.